J-L. Harousseau Tipifarnib in hematologic malignancies

JL Harousseau

doi:10.4081/hmr.v2i5.756

Abstracts

Vol. 2 No. 5 (2008)

https://doi.org/10.4081/hmr.v2i5.756

J-L. Harousseau Tipifarnib in hematologic malignancies

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

Published: 23 June 2009

232

Views

294

Downloads

Authors

JL Harousseau

support@pagepress.org

Farnesyltranferase inhibitors (FTI) are signal transduction inhibitors that block farnesylation of a number of proteins including Ras that are involved in key cellular functions (proliferation,survival and differentiation).1,2 Tipifarnib is a potent inhibitor of farnesyltransferase that is orally bioavailable. Tipifarnib was initially developed with the goal of targeting Ras in cancers with a high incidence of Ras mutations. However, after failure of large clinical trials in solid tumors (pancreas, colon) further development was mainly focused on hematologic malignancies